![Pharmaceutics International, Inc., Pii](/img/default-banner.jpg)
- 10
- 10 239
Pharmaceutics International, Inc., Pii
United States
เข้าร่วมเมื่อ 30 เม.ย. 2020
Pharmaceutics International, Inc. (Pii) is a contract development and manufacturing organization (CDMO) with a passion for solving problems efficiently with the highest quality standards.
Pii’s Hunt Valley, Maryland campus includes 70 manufacturing suites with 4 integrated aseptic filling lines delivering quality, safety, and efficiency. Our professionals have extensive experience with small and large molecule compounds, developing and manufacturing complex parenteral drugs, extended-release formulations, non-aqueous injectable drug products, and lyophilization. Learn more at www.pharm-int.com/
Pii’s Hunt Valley, Maryland campus includes 70 manufacturing suites with 4 integrated aseptic filling lines delivering quality, safety, and efficiency. Our professionals have extensive experience with small and large molecule compounds, developing and manufacturing complex parenteral drugs, extended-release formulations, non-aqueous injectable drug products, and lyophilization. Learn more at www.pharm-int.com/
Pii R&D and Analytic for Early Stage Development 012022
Early-Stage Development is in Pii’s DNA
Pii has been a proud CDMO partner for more than 28 years, supporting programs from early stages of development through commercialization. Pii’s extensive experience in understanding different analytical requirements allows us to better serve our partners’ needs. And we are proud to offer several of these capabilities in house.
Pii’s main lab has more than 70 HPLC and UPLC systems from Waters and Agilent to support a variety of complex formulations requiring specialized methods, including those for light-sensitive products. Pii’s experienced Analytical Research and Development team, working in conjunction with our Quality Control unit, will help optimize, develop, validate or verify the methods to meet our partners’ needs for programs, which range from early-phase clinical trials through late stages of tech transfer and beyond.
In addition to Pii’s LC system capabilities, we offer a variety of other testing solutions, including particle size distribution analysis using Malvern’s Zetasizer that can help determine zeta-potential and molecular size for detection of aggregates and small particles. In addition, Pii houses a Malvern Mastersizer 3000 supporting particle size analysis for particles from 0.1 micron to 3 millimeters.
Pii utilizes Agilent’s ICPMS system for elemental impurities and heavy metals analysis. The ICPMS is used to detect metals and several non-metals in liquid samples at very low concentrations. Pii leverages the in-house ICPMS to determine whether a product requires routine analysis and evaluation in conjunction with the principles of ICHQ3D, which provides guidance on the process to evaluate and control elemental impurities in the drug product through risk management.
To support our evaluation of in vitro dissolution testing, Pii has more than 20 dissolution baths supporting multiple dosage forms, including tablets, capsules, non-sterile liquids and suspensions, and even extended-release injectables. Pii’s in-house experts have the ability to develop and validate methods, and even optimize existing methods, to achieve a robust drug release profile for submission and routine analysis.
Our gas chromatography systems check for residual solvents in a drug substance, for example, to ensure these impurities, if present, are within acceptable limits.
Additionally, differential scanning calorimetry, or DSC, is important during early stages of development to measure the physical properties of changes in the state of a material, along with temperature, over time.
Pii also has the ability to support raw material testing in house, as well as analysis of physiochemical characteristics such as moisture content and pH testing.
And our ICH capability chambers range from -20 degrees Celsius to 40 degrees Celsius to support the variety of dosage forms.
All of these previously mentioned services are supported by Pii’s in-house stability testing capabilities from early development through commercialization. Pii’s in-house, analytical capabilities align with our other core development functions so that our scientific team can focus on the key product criteria to accelerate timelines and scale up formulations.
Speak to a Pii scientist today so that we can help you quickly get to a go/no go decision. Visit us at www.pharm-int.com/ or contact us at bd@pharm-int.com or call 410-584-0001
Pii has been a proud CDMO partner for more than 28 years, supporting programs from early stages of development through commercialization. Pii’s extensive experience in understanding different analytical requirements allows us to better serve our partners’ needs. And we are proud to offer several of these capabilities in house.
Pii’s main lab has more than 70 HPLC and UPLC systems from Waters and Agilent to support a variety of complex formulations requiring specialized methods, including those for light-sensitive products. Pii’s experienced Analytical Research and Development team, working in conjunction with our Quality Control unit, will help optimize, develop, validate or verify the methods to meet our partners’ needs for programs, which range from early-phase clinical trials through late stages of tech transfer and beyond.
In addition to Pii’s LC system capabilities, we offer a variety of other testing solutions, including particle size distribution analysis using Malvern’s Zetasizer that can help determine zeta-potential and molecular size for detection of aggregates and small particles. In addition, Pii houses a Malvern Mastersizer 3000 supporting particle size analysis for particles from 0.1 micron to 3 millimeters.
Pii utilizes Agilent’s ICPMS system for elemental impurities and heavy metals analysis. The ICPMS is used to detect metals and several non-metals in liquid samples at very low concentrations. Pii leverages the in-house ICPMS to determine whether a product requires routine analysis and evaluation in conjunction with the principles of ICHQ3D, which provides guidance on the process to evaluate and control elemental impurities in the drug product through risk management.
To support our evaluation of in vitro dissolution testing, Pii has more than 20 dissolution baths supporting multiple dosage forms, including tablets, capsules, non-sterile liquids and suspensions, and even extended-release injectables. Pii’s in-house experts have the ability to develop and validate methods, and even optimize existing methods, to achieve a robust drug release profile for submission and routine analysis.
Our gas chromatography systems check for residual solvents in a drug substance, for example, to ensure these impurities, if present, are within acceptable limits.
Additionally, differential scanning calorimetry, or DSC, is important during early stages of development to measure the physical properties of changes in the state of a material, along with temperature, over time.
Pii also has the ability to support raw material testing in house, as well as analysis of physiochemical characteristics such as moisture content and pH testing.
And our ICH capability chambers range from -20 degrees Celsius to 40 degrees Celsius to support the variety of dosage forms.
All of these previously mentioned services are supported by Pii’s in-house stability testing capabilities from early development through commercialization. Pii’s in-house, analytical capabilities align with our other core development functions so that our scientific team can focus on the key product criteria to accelerate timelines and scale up formulations.
Speak to a Pii scientist today so that we can help you quickly get to a go/no go decision. Visit us at www.pharm-int.com/ or contact us at bd@pharm-int.com or call 410-584-0001
มุมมอง: 469
วีดีโอ
Pii's Lyophilization Services 011822
มุมมอง 9022 ปีที่แล้ว
Developing an effective lyophilization cycle is both art and science. Our skilled and experienced team of professionals, using Millrock lyophilization technology, provide critical and scalable synergies between the development lab and manufacturing line, ensuring your outcomes are met with the highest quality and always on time. Pii will de-risk the product development process by conducting exp...
Pii's Pre-Filled Syringe Services
มุมมอง 7732 ปีที่แล้ว
Pii's Pre-Filled Syringe Services - Groninger Fill-Finish for a Range of Injectables As a CDMO, Pii has supported aseptic fill-finish manufacturing since 2006, specializing in NDAs, NCEs, DEA-scheduled products, and most recently, biologics. Pii’s Groninger syringe line supports batch sizes up to 50,000 syringes per day with pre-filled syringe sizes ranging from 1mL through 5mL. The Groninger p...
Pii's Soft Gel Manufacturing
มุมมอง 2K2 ปีที่แล้ว
Pii's Soft Gel Manufacturing Pharmaceutics International, Inc. (Pii) is a science-driven contract development and manufacturing organization (CDMO) with a single campus in Hunt Valley, MD, offering unparalleled scientific insight and depth of product knowledge while supplying high-quality dosage forms that enhance the lives of patients worldwide. Founded in 1994, Pii’s cGMP facilities are state...
Clinical Aseptic Vial Filling with M and O Perry
มุมมอง 1.6K2 ปีที่แล้ว
Flexibility for customers is what makes Pii’s M and O Perry aseptic vial filling line unique. One of four aseptic fillers at Pii, M and O Perry boasts the ability to fill up to 40 vials per minute, supporting batch sizes up to a 500-liters, and the ability to fill a vial sizes range from 3mL to 100mL. Depending on customer need, M and O Perry’s flexibility enables vials to be aseptically filled...
Pii's Robotic Small Scale Aseptic Fill-Finish Production
มุมมอง 1.3K2 ปีที่แล้ว
Pii can provide you with state-of-the-art GENiSYS R aseptic filling and closure system tailored technology for pharmaceutical and biopharmaceutical The GENiSYS R aseptic filling and closure system is: • A fully robotic, automated line • It is Pre-qualified with no additional costs for media fill qualification • And, customized in process controls supports real time batch records • The GENiSYS R...
Pii CDMO detail for large scale aseptic fill-finish production
มุมมอง 2K2 ปีที่แล้ว
With 25 years of Fill-Finish experience, Pii's experts are uniquely qualified to take on your complex formulations. Key to this process is Pii’s specialized vial filling equipment. The Bosch FWR 4020 high-speed vial filler is one of four aseptic filling lines at Pii. The Bosch filler is perfect for handling large commercialization batches, up to 200,000 vials. Vials from a 2mL with 13mm neck fi...
Pii's Sterile Parenteral Robotic, Aseptic Fill-Finish - From Concept to Clinical to Commercial.
มุมมอง 8404 ปีที่แล้ว
Pii can provide you with state-of-the-art GENiSYS R aseptic filling and closure system tailored technology for pharmaceutical and biopharmaceutical The GENiSYS R aseptic filling and closure system is: • A fully robotic, automated line, • It is Pre-qualified with no additional costs for media fill qualification • And, customized in process controls supports real time batch records • The GENiSYS ...